RSV Vaccine Receives Approval for Phase III Clinical Trial in China, Marking Another Milestone in Respiratory Specialty Drug Development
Winter and early spring are the peak seasons for respiratory syncytial virus (RSV) prevalence.RSV is a common airborne RNA virus. It spreads in a manner similar to SARS-CoV-2, typically entering the trachea and lungs via inhalation through the mouth and nose. RSV invades epithelial cells, causing cell death, and triggers the secretion of respiratory mucus that obstructs the airway lumen, leading to breathing difficulties.
RSV is one of the three major respiratory viral diseases, with children, the elderly, and immunocompromised adults being susceptible populations.Globally, RSV infection causes approximately 64 million hospitalizations for lower respiratory tract diseases and about 160,000 deaths annually. In China, the population requiring RSV prevention is nearly 400 million, with approximately 5 million high-risk elderly patients. Currently,No RSV vaccine products have been approved for marketing worldwide., RSV treatment in China is also limited to alleviating disease symptoms.
In the post-pandemic era, acceptance of vaccination for disease prevention has increased, and RSV vaccine development is rapidly advancing worldwide; however, no RSV vaccine products have yet been approved globally.Overseas, the RSV vaccines developed by Pfizer and GSK represent the most advanced pipelines at this stage., have now achieved positive data in their respective global Phase III clinical trials (excluding China), and are expected to submit New Drug Applications (NDAs) sequentially next year. (Data sources: Clinical Trial, NMPA, Janssen official website) In addition,J&J and Moderna’s RSV vaccine pipelines are also steadily advancing through their Phase III clinical trials.。
Encouragingly, several domestic pharmaceutical companies in China have also advanced their RSV vaccines into the late stages of clinical development.According to VCBeat, innovative biopharmaceutical company Yourui Pharmaceutical announced on November 14 that its Investigational New Drug (IND) application for the Phase III clinical trial of the MVA-BN RSV vaccine had been approved, and that the Phase III clinical trial would be launched in 2023.This marks Yourui Pharmaceutical’s potential to rank among the top tier in China’s RSV landscape.
The MVA-BN RSV vaccine was developed by the Danish company Bavarian Nordic, which has entrusted Yourui Pharmaceutical with full responsibility for the development and commercialization rights of the vaccine in the Asia-Pacific region.
Unlike integrated pharmaceutical companies such as Pfizer and GSK,Bavarian Nordic is a comprehensive vaccine company focused on the development, manufacturing, and commercialization of vaccines.. The company has leveraged its MVA-BN live viral vaccine platform technology to create numerous patented and collaborative candidate products.
Bavarian Nordic’s smallpox vaccine currently holds a leading position globally. Following its approval by the U.S. Food and Drug Administration (FDA), it became the long-term supplier of non-replicating smallpox vaccines to the U.S. government, and has also been approved for use as a smallpox vaccine by the governments of Europe and Canada. Furthermore, the vaccine has demonstrated outstanding efficacy in preventing monkeypox, leading to the successive signing of supply agreements with countries and regions across Europe, Latin America, and the Asia-Pacific, thereby generating substantial market demand worldwide.
Based on Bavarian Nordic’s high-level expertise in vaccine development,The MVA-BN-RSV vaccine encodes five different RSV antigens., it has received Breakthrough Therapy Designation from the FDA and Priority Medicines (PRIME) designation from the EMA this year. The vaccine is currently indicated for active immunization in adults aged 60 years or older to prevent lower respiratory tract disease caused by RSV.
In April this year, Bavarian Nordic initiated a global, randomized, double-blind Phase III trial of the vaccine, involving 20,000 adults aged 60 years and older. The trial will span the 2022–2023 RSV season and aims to evaluate the efficacy of the candidate vaccine versus placebo in preventing lower respiratory tract disease caused by RSV. Currently, the trial is being conducted at approximately 115 sites in the United States and Germany (excluding sites in China), with top-line results expected in mid-2023.
According to the latest clinical research progress disclosed on the official website, the vaccine demonstrated good tolerability and was able to induce broad and durable antibody and T-cell responses against RSV, as well as mucosal immune responses that may play an important role in preventing RSV. A second dose administered to participants one year later resulted in a rapid and significant boost in immune responses, which was most pronounced in those with weaker immunity prior to receiving the booster vaccine.
Next, the new drug clinical trial of the MVA-BN RSV vaccine in China is a randomized, double-blind, Phase III clinical trial evaluating the clinical efficacy, safety, and reactogenicity of the recombinant MVA-BN RSV vaccine in adults aged ≥60 years.Based on positive data from Phase II clinical trials and the current pace of development in this sector, the MVA-BN RSV vaccine is highly likely to rapidly capture the RSV vaccine market in China and across the broader Asia-Pacific region.
Yourui Pharmaceutical Has Earned Full Recognition from Bavarian Nordic, and secured the rights for the research, development, and commercialization of the MVA-BN RSV vaccine in the Asia-Pacific region, not only based on Yourui PharmaceuticalTechnical Expertise in Respiratory Diseases, andSuccessful Experience in Commercializing Multiple Products in the Asia-Pacific Region。
Mr. Mark Lotter, Founder and CEO of Yourui PharmaceuticalAs one of AstraZeneca’s first executives to come to China, he not only pioneered AstraZeneca China’s respiratory inhalation strategy but also established its commercial framework. Under Mr. Mark’s leadership,Yourui Pharmaceutical has developed a leading innovative pipeline in the respiratory disease field within the Asia-Pacific region, successfully introducing three first-in-class (FIC) therapies and securing “blockbuster”-potential products across three major respiratory diseases.。
The company has introduced Ensifentrine, a nebulized treatment for COPD, asthma, and cystic fibrosis, and Aerofact, a non-invasive therapy for neonatal respiratory distress syndrome.TM, and Bentrio, a protective nasal spray that prevents the airborne transmission of allergens and virusesTM, this nasal spray can effectively prevent COVID-19 and has recently been launched for sale in Hong Kong, China.
In addition to its current pipeline of respiratory disease candidates under development, Yourui Pharmaceutical has successfully commercialized multiple products, transitioning them from clinical trials to market sales. By focusing on specialized pharmaceuticals, the company has established a mature commercialization platform. Its launched products have consistently maintained strong double-digit sales growth, robustly validating the efficacy of its commercial marketing model.
Notably,Yourui Pharmaceutical did not follow the “going global” wave into markets such as the United States and Europe; instead, it chose regions with equally strong medical demand, including China’s Hong Kong, Macao, and Taiwan, as well as South Korea, Singapore, and Thailand.Leveraging multiple advantages—including cultural, policy, and geographic factors—to establish differentiated models for commercial conversion. Currently, Yourui Pharmaceutical has built a robust commercial engine encompassing sales and agency capabilities targeted at hospitals, OTC retail, and DTC channels. Through self-sustaining commercial operations, the company has achieved stable cash-generating capabilities.
Within one year, successively obtained Phase III clinical IND approvals for Ensifentrine and the MVA-BN RSV vaccine, both with First-in-Class potential, and collaborated with top academician experts to lead clinical trials in China.Yourui Pharmaceutical Is Accelerating the Development of a Top-Tier Innovative Pipeline in the Asia-Pacific Respiratory Field。
Rather than entering the fiercely competitive arenas of oncology and immunology, it has focused on specializing in specialty drugs for respiratory diseases. Instead of competing in drug discovery and preclinical research, it has achieved repeated success in late-stage clinical development and commercial translation. Rather than blindly pursuing market share in the United States and Europe, it has been steadily expanding across the Asia-Pacific region.Yourui Pharmaceutical has successfully established differentiated advantages across three distinct dimensions—therapeutic areas, business models, and sales markets—through its series of “distinctive” initiatives, achieving remarkable phased results in various aspects.
Yourui Pharmaceutical’s commercially driven strategy is vibrant in the current market and holds great promise!